{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:53:01Z","timestamp":1792511581176,"version":"4.5.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2012,4,17]],"date-time":"2012-04-17T00:00:00Z","timestamp":1334620800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2012,4,17]],"date-time":"2012-04-17T00:00:00Z","timestamp":1334620800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2012,11]]},"DOI":"10.1038\/leu.2012.107","type":"journal-article","created":{"date-parts":[[2012,4,17]],"date-time":"2012-04-17T06:37:42Z","timestamp":1334644662000},"page":"2398-2405","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":72,"title":["Primary plasma cell leukemia: clinical and laboratory presentation, gene-expression profiling and clinical outcome with Total Therapy protocols"],"prefix":"10.1038","volume":"26","author":[{"given":"S Z","family":"Usmani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"Nair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Q","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N","family":"Petty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Waheed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"J D","family":"Shaughnessy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y","family":"Alsayed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C J","family":"Heuck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"van Rhee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Milner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Hoering","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Szymonifka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Sexton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Sawyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Crowley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"Barlogie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,4,17]]},"reference":[{"key":"BFleu2012107_CR1","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1111\/j.1365-2141.1994.tb05114.x","volume":"88","author":"MA Dimopoulos","year":"1994","unstructured":"Dimopoulos MA, Palumbo A, Delasalle KB, Alexanian R . Primary plasma cell leukemia. Br J Haematol 1994; 88: 754\u2013759.","journal-title":"Br J Haematol"},{"key":"BFleu2012107_CR2","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1001\/archinte.133.5.813","volume":"133","author":"RA Kyle","year":"1974","unstructured":"Kyle RA, Maldonado JE, Bayrd ED . Plasma cell leukemia: a report on 17 cases. Arch Intern Med 1974; 133: 813\u2013818.","journal-title":"Arch Intern Med"},{"key":"BFleu2012107_CR3","doi-asserted-by":"publisher","first-page":"2276","DOI":"10.1182\/blood-2005-05-1858","volume":"106","author":"GS Nowakowski","year":"2005","unstructured":"Nowakowski GS, Witzig TE, Dingli D, Tracz MJ, Gertz MA, Lacy MQ et al. Circulating plasma cells detected by flow cytometry as a predictor of survival in 302 patients with newly diagnosed multiple myeloma. Blood 2005; 106: 2276\u20132279.","journal-title":"Blood"},{"key":"BFleu2012107_CR4","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1016\/0002-9343(87)90942-9","volume":"83","author":"P Noel","year":"1987","unstructured":"Noel P, Kyle RA . Plasma cell leukemia: an evaluation of response to therapy. Am J Med 1987; 83: 1062\u20131068.","journal-title":"Am J Med"},{"key":"BFleu2012107_CR5","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1200\/JCO.2005.04.5807","volume":"24","author":"B Barlogie","year":"2006","unstructured":"Barlogie B, Kyle RA, Anderson KC, Greipp PR, Lazarus HM, Hurd DD et al. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. J Clin Oncol 2006; 24: 929\u2013936.","journal-title":"J Clin Oncol"},{"key":"BFleu2012107_CR6","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1056\/NEJMoa053583","volume":"354","author":"B Barlogie","year":"2003","unstructured":"Barlogie B, Tricot G, Anaissie E, Shaughnessy J, Rasmussen E, van Rhee F et al. Thalidomide and hematopoetic-cell transplantation for multiple myeloma. N Engl J Med 2003; 354: 1021\u20131030.","journal-title":"N Engl J Med"},{"key":"BFleu2012107_CR7","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1111\/j.1365-2141.2007.06639.x","volume":"138","author":"B Barlogie","year":"2007","unstructured":"Barlogie B, Anaissie E, van Rhee F, Haessler J, Hollmig K, Pineda-Roman M et al. Incorporating bortezomib into upfront treatment for multiple myeloma: early results of Total Therapy 3. Br J Haematol 2007; 138: 176\u2013185.","journal-title":"Br J Haematol"},{"key":"BFleu2012107_CR8","doi-asserted-by":"publisher","first-page":"4168","DOI":"10.1182\/blood-2009-11-255620","volume":"115","author":"B Nair","year":"2010","unstructured":"Nair B, van Rhee F, Shaughnessy JD, Anaissie E, Szymonifka J, Hoering A et al. Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with bortezomib, lenalidomide and dexamethasone (VRD) maintenance. Blood 2010; 115: 4168\u201373.","journal-title":"Blood"},{"key":"BFleu2012107_CR9","doi-asserted-by":"publisher","first-page":"2276","DOI":"10.1182\/blood-2006-07-038430","volume":"109","author":"JD Shaughnessy","year":"2007","unstructured":"Shaughnessy JD, Zhan F, Burington BE, Huang Y, Colla S, Hanamura I et al. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood 2007; 109: 2276\u20132284.","journal-title":"Blood"},{"key":"BFleu2012107_CR10","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1046\/j.1365-2141.1998.00930.x","volume":"102","author":"J Blad\u00e9","year":"1998","unstructured":"Blad\u00e9 J, Samson D, Reece D, Apperley J, Bj\u00f6rkstrand B, Gahrton G et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998; 102: 1115\u20131123.","journal-title":"Br J Haematol"},{"key":"BFleu2012107_CR11","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","volume":"20","author":"BG Durie","year":"2006","unstructured":"Durie BG, Harousseau JL, Miguel JS, Blad\u00e9 J, Barlogie B, Anderson K et al. International uniform response criteria for multiple myeloma. Leukemia 2006; 20: 1467\u20131473.","journal-title":"Leukemia"},{"key":"BFleu2012107_CR12","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1182\/blood.V93.3.1032","volume":"93","author":"R Garcia-Sanz","year":"1999","unstructured":"Garcia-Sanz R, Orfao A, Gonzalez M, Tabernero MD, Blad\u00e9 J, Moro MJ et al. Primary plasma cell leukemia: clinical, immunophenotypic, DNA ploidy and cytogenetic characteristics. Blood 1999; 93: 1032\u20131037.","journal-title":"Blood"},{"key":"BFleu2012107_CR13","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","volume":"53","author":"EL Kaplan","year":"1958","unstructured":"Kaplan EL, Meier P . Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457\u2013481.","journal-title":"J Am Stat Assoc"},{"key":"BFleu2012107_CR14","doi-asserted-by":"publisher","first-page":"3512","DOI":"10.1182\/blood-2010-12-328252","volume":"118","author":"JD Shaughnessy","year":"2011","unstructured":"Shaughnessy JD, Qu P, Usmani S, Heuck CJ, Zhang Q, Zhou Y et al. Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3. Blood 2011; 118: 3512\u201324.","journal-title":"Blood"},{"key":"BFleu2012107_CR15","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1182\/blood-2005-11-013458","volume":"108","author":"F Zhan","year":"2006","unstructured":"Zhan F, Huang Y, Colla S, Stewart JP, Hanamura I, Gupta S et al. The molecular classification of multiple myeloma. Blood 2006; 108: 2020\u20132028.","journal-title":"Blood"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/leu2012107.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2012107","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2012107.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T15:17:02Z","timestamp":1648739822000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu2012107"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4,17]]},"references-count":15,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2012,11]]}},"alternative-id":["BFleu2012107"],"URL":"https:\/\/doi.org\/10.1038\/leu.2012.107","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,4,17]]},"assertion":[{"value":"3 February 2012","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 March 2012","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2012","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2012","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr Shaughnessy is a founder of and has an ownership stake in Signal Genetics, LLC, a biotechnology company that has licensed technology from the University of Arkansas for purposes of commercial development. He holds patents, or has submitted patent applications, on the use of GEP in cancer medicine. Dr Shaughnessy receives royalties related to patent licenses from Genzyme Novartis and Signal Genetics. He has received research funding from Celgene, Millennium and Novartis. He has advised Celgene, Genzyme, Millennium and Novartis, and has received speaking honoraria from Celgene, ArrayBioPharma, Centocor Ortho Biotech, Genzyme, Millennium and Novartis. Dr Barlogie has received research funding from Celgene and Novartis. He is a consultant to Celgene and Genzyme, and has received speaking honoraria from Celgene and Millennium. Dr Barlogie is a co-inventor on patents and patent applications related to use of GEP in cancer medicine. Dr Usmani is a consultant to Celgene, Millennium and Onyx. He has received research funding from Onyx and speaking honoraria from Celgene. All other authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}